Speech-Language Pathologists in Pierre, SD Accepting Medicare

6 Speech-Language Pathologists found. Showing 1 - 6

Ms. Kim Meyer Roberts, MA,CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 211 S Poplar Ave, Pierre, SD 57501 Phone: 605-773-7300

Brenda Nedved, MA CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 211 S Poplar Ave, Pierre, SD 57501 Phone: 605-773-7300

Aimee Van Houten, M.A. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 900 N Poplar Ave, Pierre, SD 57501 Phone: 605-773-7320

Kelsee Stahl, M.A. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 211 S Poplar Ave, Pierre, SD 57501 Phone: 605-773-7300

Jaculin Protexter, MA Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 1118 Woodriver Dr, Pierre, SD 57501 Phone: 605-280-7510

Mrs. Sharon B. Hoelscher, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 950 E Park St, Pierre, SD 57501 Phone: 605-224-8628    Fax: 605-224-6948

News Archive

FDA examines deaths of patients using pain patches

The U.S. Food and Drug Administration (FDA) is investigating reports of the deaths of patients who were using pain patches that contain the narcotic fentanyl.

Multicenter trial compares popular treatments for menopause-related vaginal symptoms

Hot flashes. Night sweats. These are the most common - or at least the most commonly talked about - symptoms of menopause. But one reality of The Change for many women is less discussed yet no less important: problems with vaginal health and sexual function.

Potential new therapy for lung disease patients

A new study by researchers at Northwestern University's Feinberg School of Medicine may change current thinking about how best to treat patients in respiratory distress in hospital intensive care units.

S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies

S*BIO Pte Ltd today announced that a fourth novel, potential best-in-class compound discovered and developed by S*BIO has entered a Phase 1 clinical trial. The initiation of the study for S*BIO's oral multi-kinase inhibitor, SB1317 or TG02, in patients with advanced/refractory hematologic malignancies has triggered a payment from S*BIO's development and commercialization partner for the program, Tragara Pharmaceuticals.

MorphoSys to start share buy-back

MorphoSys AG announced today the decision to repurchase its own shares on the stock market. Following approval by the Company's Supervisory Board, the Board of Management of MorphoSys AG has resolved to acquire up to 100,000 MorphoSys shares over the stock market during the time period from June 1, 2011 to June 30, 2011. The shares will be used to implement the Company's long-term incentive program for management.

Read more Medical News

› Verified 6 days ago